DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Small Study / Early Comparative Evidence
VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss, distinct from off-label use of cardiovascular minoxidil. Topline phase 2/3 data come from a 519-patient randomized, double-blind, placebo-controlled trial in men ages 18 to 65 with mild to moderate androgenetic alopecia.
Clinical Considerations
- Once- and twice-daily dosing produced 30.3 and 33.0 hairs/cm² gains versus 7.3 with placebo at six months (both P<.0001).
- Statistically significant hair growth appeared as early as two months, suggesting rapid onset relative to existing options.
- Patient-reported “improved” or “much improved” coverage reached 48.4% and 62.9% in active arms versus 13.4% with placebo.
- Discontinuation rates were lower in active arms than placebo, with safety consistent with prior off-label oral minoxidil use.
Practice Applications
- Recognize VDPHL01 as a pipeline product, not yet FDA-approved, distinct from compounded low-dose oral minoxidil.
- Interpret topline results cautiously pending peer review and the second phase 3 trial readout in late 2026.
- Monitor patients currently on off-label oral minoxidil for cardiovascular and dermatologic adverse effects.
- Consider counseling patients asking about oral options that an approved formulation may be forthcoming.
More in Alopecia
